Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Idebenone (Raxone®) is recommended for use within NHS Wales for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON). This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | idebenone (Raxone®) | ||
| Formulation | 150 mg film-coated tablet | ||
| Reference number | 807 | ||
| Indication | Treatment of visual impairment in adolescent and adult patients with Leber’s hereditary optic neuropathy |
||
| Company | Chiesi Ltd | ||
| BNF chapter | Eye | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 0521 | ||
| NMG meeting date | 04/11/2020 | ||
| AWMSG meeting date | 10/03/2021 | ||
| Date of issue | 17/03/2021 | ||
| Commercial arrangement | WPAS | ||